Congressional interest in rescheduling ibogaine has accelerated sharply, driven by a convergence of veteran advocacy, peer-reviewed clinical data, and bipartisan legislation. Several bills have been introduced in recent sessions to move ibogaine out of Schedule I — the most restrictive federal drug category — while a landmark Department of Defense study has added scientific weight to those efforts. No rescheduling has occurred yet, but the legislative landscape is shifting faster than at any previous point in ibogaine's modern history.

What Does Schedule I Actually Mean for Ibogaine?

Under the Controlled Substances Act (21 U.S.C. § 812), a Schedule I substance is defined as having no currently accepted medical use, a high potential for abuse, and a lack of accepted safety data for use under medical supervision. Ibogaine was placed in Schedule I in 1970, before any substantial clinical research had been conducted in the United States.

The practical consequences are severe. Schedule I status makes it illegal to possess, distribute, or administer ibogaine in the US outside of a DEA-licensed research context. It blocks FDA approval pathways that depend on domestic prescribing data, prevents insurance coverage, and — critically — prevents the Department of Veterans Affairs from providing or even formally recommending the treatment to eligible veterans. Researchers must navigate a costly and slow DEA Schedule I researcher registration process before any human trials can begin.

Which Bills Has Congress Introduced?

The most prominent recent legislation is the Ibogaine Research and Accessibility Act (S.3032), introduced in the 118th Congress. The bill proposed transferring ibogaine to Schedule III, funding clinical research, and creating a pathway for supervised therapeutic access. It did not advance to a floor vote, but it established ibogaine as a named legislative priority for the first time.

Separately, the National Defense Authorization Act for Fiscal Year 2025 (NDAA FY2025, Section 1093, Pub. L. 118-159) — a bill that did become law — directed the Department of Defense to conduct or support clinical research into ibogaine as a treatment for traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) in military service members and veterans. This provision did not reschedule ibogaine, but it represents the first time Congress explicitly mandated federal funding for ibogaine research, a significant symbolic and procedural milestone.

What Role Are Veterans Playing in the Advocacy Push?

Veterans have become the most visible and politically resonant voice for ibogaine access. The argument is direct: thousands of veterans with treatment-resistant PTSD and TBI are traveling to clinics in Mexico and other countries to receive ibogaine therapy because it is unavailable at home. Organizations including the Veterans Exploring Treatment Solutions (VETS) and Heroic Hearts Project have documented hundreds of cases and funded observational studies.

The peer-reviewed publication that most directly influenced Congressional debate was a 2024 Nature Medicine study by Murray et al. examining a cohort of US Special Operations Forces veterans who received ibogaine-assisted therapy at a clinic in Mexico. The study found significant reductions in PTSD symptom severity, depression, and suicidal ideation, alongside improvements in cognitive function — particularly notable given TBI comorbidities. Researchers at Stanford University were involved in the analysis, lending academic credibility that reached congressional staff briefings and hearing testimony.

Safety Note: The Murray et al. (2024) study was observational and conducted at a private clinic without randomized controls. Ibogaine carries documented risks of cardiac arrhythmia, including QTc prolongation, and deaths have occurred in unscreened individuals. The veterans in the study underwent cardiac screening, but this protocol is not uniformly applied outside supervised research settings. Congressional proposals universally include medical screening requirements for any legal access framework.

What Is the Stanford VA Ibogaine Trial?

The Stanford VA trial (ClinicalTrials.gov identifier NCT05765188) is the first ibogaine study formally linked to a US Department of Veterans Affairs institution. The trial is examining safety, tolerability, and preliminary efficacy of ibogaine for veterans with PTSD and TBI, conducted in collaboration with researchers who have operational experience with the compound. The trial design includes rigorous cardiac screening — including baseline electrocardiograms and exclusion criteria for QTc abnormalities — and is conducted under an FDA Investigational New Drug (IND) application, meaning the FDA has reviewed and permitted the protocol despite ibogaine's Schedule I status.

This trial matters legislatively because it is building the kind of US-based, IRB-approved, FDA-supervised dataset that would be required to support any formal rescheduling petition submitted to the DEA or initiated by the FDA under 21 U.S.C. § 811.

How Does Rescheduling Actually Happen?

There are two primary pathways. First, the DEA can initiate rescheduling on its own or upon petition from any interested party, including a drug manufacturer, a medical association, or a member of the public. The DEA must then request a scientific and medical evaluation from the FDA, which applies an eight-factor analysis. This process is lengthy and has historically been slow.

Second, Congress can reschedule directly through statute, bypassing the DEA-FDA administrative process. This is the approach taken in bills like the Ibogaine Research and Accessibility Act, and it is the faster — though politically harder — route. A hybrid approach, exemplified by the NDAA Section 1093 strategy, uses legislative mandates to force research that will eventually feed into the administrative rescheduling process.

Advocates frequently point to the precedent set by ketamine, which remains Schedule III and is legally prescribed as esketamine (Spravato, FDA-approved 2019) for treatment-resistant depression. Ketamine's trajectory — from anesthetic to Schedule III to FDA-approved psychiatric drug — is often cited as the model ibogaine proponents hope to replicate.

What Are the Main Obstacles to Rescheduling?

Several structural barriers complicate the path forward. The cardiac safety profile of ibogaine is the most frequently cited concern among FDA reviewers and skeptical legislators. Ibogaine prolongs the QTc interval on electrocardiograms, a known risk factor for potentially fatal arrhythmias. At least several dozen deaths have been associated with ibogaine globally, though most involve pre-existing cardiac conditions, polysubstance use, or inadequate screening. Designing an access framework that minimizes this risk — while still making treatment accessible — is a genuine regulatory challenge.

There is also the question of commercial infrastructure. Unlike MDMA or psilocybin, ibogaine has no well-capitalized pharmaceutical sponsor currently shepherding it through Phase 3 trials toward an NDA submission. The MAPS PBC MDMA experience — which saw FDA reject its NDA application based on trial design concerns in 2024 — has also made Congressional staff more cautious about assumptions that psychedelic compounds will move smoothly through regulatory review.

Finally, political will remains inconsistent. While ibogaine enjoys unusual bipartisan support — connecting libertarian-leaning veteran advocacy with progressive drug reform constituencies — the broader political environment for psychedelic policy reform has become more contested, particularly in an era of heightened concern about drug policy messaging.

Frequently Asked Questions

Ibogaine is Schedule I federally, making it illegal to possess or administer in all US states except in the context of a DEA-licensed research program operating under an FDA Investigational New Drug application. No state has independently legalized ibogaine for therapeutic use, though several have passed resolutions supporting research.
No. Section 1093 of the NDAA FY2025 directed the Department of Defense to fund or conduct clinical research on ibogaine for TBI and PTSD in veterans and service members. It did not alter ibogaine's Schedule I classification. It is best understood as a research mandate, not a legal access provision.
The Ibogaine Research and Accessibility Act proposed reclassifying ibogaine to Schedule III, the same schedule as ketamine and anabolic steroids. Schedule III allows for prescribing by licensed practitioners, insurance billing, and conventional pharmaceutical development, while still maintaining regulatory controls.
Ibogaine prolongs the QTc interval, a measure of cardiac repolarization. Prolonged QTc can predispose individuals to a potentially fatal arrhythmia called torsades de pointes. Risk is elevated in people with pre-existing cardiac conditions, electrolyte imbalances, or who are taking other QTc-prolonging medications. Clinical protocols in research settings require cardiac screening, including ECG, before administration.
No. The VA cannot prescribe, administer, or reimburse ibogaine under its current legal status. Veterans who have sought ibogaine treatment have done so by traveling to clinics in Mexico, Canada, or other countries at their own expense. Some nonprofit organizations provide financial assistance for this travel, but no federal program currently covers it.
The DEA-FDA administrative rescheduling process has historically taken many years. The marijuana rescheduling review initiated in the early 2020s illustrates the pace: petitions filed decades ago are still working through the system. Congressional rescheduling via statute can be faster in theory, but requires sufficient political momentum to pass both chambers and survive presidential review.
Yes. Ibogaine is not scheduled in Mexico, which hosts a significant number of clinics serving international patients including Americans. It is also unscheduled or minimally regulated in several other countries. In Gabon, ibogaine-containing Tabernanthe iboga is used in traditional Bwiti ceremonies and is considered a cultural heritage substance. New Zealand has classified ibogaine as a prescription medicine rather than a prohibited drug.

The legislative trajectory around ibogaine is moving, but it remains in an early and legally complex stage. If you or someone you know is researching ibogaine — whether for addiction, PTSD, TBI, or depression — consulting with a physician familiar with psychedelic medicine, a legal professional aware of current federal and state law, and any ongoing clinical trial coordinators is strongly recommended before making any decisions about treatment. Enrolling in a registered clinical trial is currently the only legal path to ibogaine access within the United States.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.